Indium-111-labeled anti-egfr-425 scintigraphy in the detection of malignant gliomas

Abstract

Background. The monoclonal antibody anti‐epidermal growth factor receptor (EGFr)antibody‐425, against the epidermal growth factor receptor, has the potential to bind specifically to gliomas and not normal brain tissue.1–3 A prospective study was conducted (1986–1988) to evaluate the use of Indium‐111 (111In)‐labeled anti‐EGFr‐425 in the localization of gliomas before radioimmunotherapy with Iodine‐125 (125I)‐labeled anti‐EGFr‐425. Methods. Twenty‐eight patients with intracranial neoplasms were injected intravenously with an average dose of 2.2 mCi 111In‐labeled anti‐EGFr‐425. Planar and single‐photon emission computed tomography scans were performed after 48 and 72 hours. Control studies also were performed in two cases with 111In‐labeled Co 17‐1A (a, *I antibody to colorectal cancer) and in one case with unlabeled 111In chloride. Results. The immunoscintigraphic findings were generally in good agreement with computerized tomographic findings. The definitive diagnosis was established by biopsy findings: 23 gliomas (1 Grade I, 5 Grade II, 6 Grade III, and 11 Grade IV), 1 meningioma, and 4 metastatic lesions. The localization of gliomas with 111In‐labeled anti‐EGF‐425 had a sensitivity of 0.96, a specificity of 0.60 and an accuracy of 0.90. Conclusion. Immunoscintigraphy with 111‐In labeled anti‐EGFr‐425 can be useful in the management of malignant gliomas, especially before radioimmunotherapy with 125I‐labeled anti‐EGFr‐425. Cancer 1994; 73:884–9.

PET-Based Biodistribution and Radiation Dosimetry of Epidermal Growth Factor Receptor–Selective Tracer 11C-PD153035 in Humans

“…EGFR antibody and EGF can be radiolabeled as EGFR molecular imaging probes (20)(21)(22)(23). However, they can only detect the level of EGFR expression on the cell membrane; they cannot detect intracellular TK activity directly or determine the status of the EGFR signaling pathway accurately.…”

Phase I Clinical Evaluation of a Neutralizing Monoclonal Antibody Against Epidermal Growth Factor Receptor in Advanced Brain Tumor Patients: Preliminary Study

“…(20,21) Consequently, several EGF-R blocking or radiolabeled antibodies have been evaluated in the management of advanced brain cancer. (17,(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34) This report summarizes the results of using another neutralizing EGF-R MAb in nine patients carrying unresectable or recurrent brain tumors.…”

“…Other authors had also reported that anti-EGF-R MAbs could reach the brain tumors after intravenous or intraarterial administration. (23)(24)(25)(26)(27)(28) EGF-R detection in brain tumors largely depends on the analytical technique used. (7,24,26,(35)(36)(37)(38) In our trial, selective accumulation of 99m Tc labeled ior egf/r3 was observed in all the evaluated subjects.…”

“…The localization of gliomas using 111 Indium anti EGFR 425 (mouse IgG 2a , EMD 55900, Merck KGaA) in 28 patients, had a sensitivity of 0.96, a specificity of 0.60 and an accuracy of 0.90. (26) In a different study, positive tumor uptake was seen in eight of nine patients, using the same radioimmunoconjugate in patients bearing malignant gliomas. (24) Safety was the endpoint of the trial.…”

[111In]Bz-DTPA-hEGF: Preparation andIn VitroCharacterization of a Potential Anti-Glioblastoma Targeting Agent

“…[14][15][16][17] Earlier, an indium-111 labeled anti-EGFR antibody 425 was successfully used for detection of malignant gliomas. 18 However, the use of intact antibodies (MW < 150 kDa) might complicate the diffusion through healthy tissue and into a tumor. An alternative to anti-EGFR antibodies might therefore be to use the natural ligand, the epidermal growth factor, EGF (MW < 6 kDa), as a targeting vector for the delivery of radionuclides to tumor cells.…”